Search Options Stock News and Analysis from Schaeffer's

Struggling Biotech Name to Report Earnings After the Close

https://www.schaeffersresearch.com/content/news/2022/02/22/struggling-biotech-name-to-report-earnings-after-the-close

2/22/2022 2:34 PM

Halozyme Therapeutics Inc (NASDAQ:HALO) is gearing up for its fourth-quarter earnings report, due out after the close today, in which the company is expected to post profits of 41 cents per share. HAL...

Reliable Biotech Stock Signal Flashing Again

https://www.schaeffersresearch.com/content/analysis/2020/11/04/reliable-biotech-stock-signal-flashing-again

11/4/2020 2:52 PM

The shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) are up 3.6% to trade at $32.77 at last check, after earlier hitting an all-time high of $33.23. And while the biotech stock already enjoys an i...

Signal Says Biotech Stock Isn't Done Climbing Yet

https://www.schaeffersresearch.com/content/analysis/2020/10/20/signal-says-biotech-stock-isnt-done-climbing-yet

10/20/2020 1:38 PM

The shares of Halozyme Therapeutics, Inc (NASDAQ:HALO) are up 3.6% to trade at $30.54 at last check, after earlier hitting an all-time-high of $30.88. And while the biotech company already enjoys an i...

Long-Term Signal Says Buy This Biotech

https://www.schaeffersresearch.com/content/analysis/2019/11/07/long-term-signal-says-buy-this-biotech

11/7/2019 12:56 PM

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is trading 1.2% lower today at $16.70, taking a breather after a 10.5% gap higher on Tuesday following corporate restructuring news. Despite today's pullback,...

Halozyme Therapeutics Stock Gutted By Revenue Miss, Downgrade

https://www.schaeffersresearch.com/content/news/2018/05/11/halozyme-therapeutics-stock-gutted-by-revenue-miss-downgrade

5/11/2018 10:03 AM

Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is down 9.3% to trade at $18.12 this morning, after the biotech company reported first-quarter revenue short of analysts' forecasts, as well as a weaker...

PEOPLE ALSO SEARCH FOR